Tenaya Therapeutics Statistics
Total Valuation
TNYA has a market cap or net worth of $149.95 million. The enterprise value is $60.23 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TNYA has 217.00 million shares outstanding. The number of shares has increased by 80.34% in one year.
| Current Share Class | 217.00M |
| Shares Outstanding | 217.00M |
| Shares Change (YoY) | +80.34% |
| Shares Change (QoQ) | +7.16% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 27.58% |
| Float | 166.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.84, with a Debt / Equity ratio of 0.09.
| Current Ratio | 6.84 |
| Quick Ratio | 6.51 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -83.84% and return on invested capital (ROIC) is -48.50%.
| Return on Equity (ROE) | -83.84% |
| Return on Assets (ROA) | -43.72% |
| Return on Invested Capital (ROIC) | -48.50% |
| Return on Capital Employed (ROCE) | -70.98% |
| Weighted Average Cost of Capital (WACC) | 19.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 70 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +40.68% in the last 52 weeks. The beta is 2.99, so TNYA's price volatility has been higher than the market average.
| Beta (5Y) | 2.99 |
| 52-Week Price Change | +40.68% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 1.03 |
| Relative Strength Index (RSI) | 46.55 |
| Average Volume (20 Days) | 3,002,648 |
Short Selling Information
The latest short interest is 26.08 million, so 12.02% of the outstanding shares have been sold short.
| Short Interest | 26.08M |
| Short Previous Month | 25.19M |
| Short % of Shares Out | 12.02% |
| Short % of Float | 15.64% |
| Short Ratio (days to cover) | 8.79 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -93.33M |
| Pretax Income | -90.60M |
| Net Income | -90.60M |
| EBITDA | -84.90M |
| EBIT | -93.33M |
| Earnings Per Share (EPS) | -$0.59 |
Full Income Statement Balance Sheet
The company has $100.55 million in cash and $10.83 million in debt, giving a net cash position of $89.72 million or $0.41 per share.
| Cash & Cash Equivalents | 100.55M |
| Total Debt | 10.83M |
| Net Cash | 89.72M |
| Net Cash Per Share | $0.41 |
| Equity (Book Value) | 123.27M |
| Book Value Per Share | 0.57 |
| Working Capital | 90.15M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$68.26 million and capital expenditures -$618,000, giving a free cash flow of -$68.88 million.
| Operating Cash Flow | -68.26M |
| Capital Expenditures | -618,000 |
| Depreciation & Amortization | 8.44M |
| Net Borrowing | n/a |
| Free Cash Flow | -68.88M |
| FCF Per Share | -$0.32 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |